Cantargia AB: Cantargia reports positive results in ongoing
-
Merrill Lynch og Morgan Stanley fortsætter desværre udsalget....uanset hvilke nyheder der kommer.
-
Lad os håbe det, og at "banditterne" snart
stopper deres udsalg -
MSE 66.058 209.627 -143.569
MLEX 100.224 231.079 -130.855 -
Cantargia, Capital Markets Day, 2021
May 20th 2021 15:00 (Europe/Stockholm)
Language:
English
Speaker:
CEO, Göran Forsberg. VP Research, David Liberg. CMO, Ignacio Garcia-Ribas. Ahmad Awada, Professor at Institut Jules Bordet and Manuel Hidalgo Medina, M.D. Ph.D. Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine.
Sector:
Health care - Pharmaceuticals & Biotechnology
Listing:
Mid Cap
Activity:
Capital Markets DayTilmelding:
-
Utroligt kursen ikke stiger mere, men god mulighed for at supplere lidt op... Redeye bedömer att nya data från CANFOUR-studien i bukspottkörtelcancer kring överlevnad och längd på behandlingssvar är tydligt lovande.
Cantargia redovisar data kring behandlingseffekt avseende progressionsfri överlevnad (PFS) och total överlevnad från patienter med bukspottkörtelcancer som har behandlats med CAN04 plus cellgiftsbehandlingen gemcitabin/nab-paclitaxel i fas IIa-studien CANFOUR. -
Ligner en færdig aktie...20% ned på 2 dage
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind